Can I Take Resveratrol with Prolia (Denosumab)?

How Denosumab Works in Bone

Denosumab is a fully human monoclonal IgG2 antibody that binds RANK ligand (RANKL) with high affinity, blocking osteoclast formation, function, and survival. The FREEDOM trial (N=7,808) showed that 60 mg administered subcutaneously every 6 months reduced new vertebral fractures by 68%, hip fractures by 40%, and non-vertebral fractures by 20% over 36 months compared with placebo (P<0.001 for all three endpoints). [1]

Because it is a large protein, denosumab does not pass through hepatic cytochrome P450 enzymes. It is cleared through the reticuloendothelial system via proteolytic degradation into amino acids and small peptides, the same route as endogenous immunoglobulins. This single fact is what most separates it from small-molecule osteoporosis drugs like bisphosphonates or raloxifene.

RANKL Biology and Why It Matters for Supplement Interactions

RANK ligand is produced primarily by osteoblasts and activated T cells. It binds the RANK receptor on osteoclast precursors, triggering differentiation into mature, bone-resorbing osteoclasts. Denosumab intercepts this signal completely. Any supplement that independently modulates osteoblast or osteoclast activity, through estrogen receptors, Wnt signaling, or NF-kB pathways, therefore has a theoretical pharmacodynamic overlap with denosumab, even without touching its pharmacokinetics.

Denosumab Half-Life and Dosing Window

The mean half-life of denosumab is approximately 25.4 days, with peak serum concentrations around day 10 after a subcutaneous injection. [2] By month 6, serum levels are near the lower limit of quantification, which is precisely why the 6-month dosing interval exists. This pharmacokinetic profile means the drug is biologically active for most of the dosing interval. Supplement interactions are theoretically possible throughout that window, not just near the injection date.

What Is Resveratrol and Why Do People Take It with Osteoporosis?

Resveratrol (3,5,4'-trihydroxystilbene) is a polyphenol found in grape skins, red wine, peanuts, and Japanese knotweed (Polygonum cuspidatum). The typical dietary intake from food is well under 1 mg/day; OTC supplements generally deliver 150 to 1,000 mg/day of trans-resveratrol, the biologically active isomer.

Interest in resveratrol for bone health traces back to sirtuin-1 (SIRT1) activation research and to its partial agonist activity at estrogen receptor beta (ERβ). The hypothesis is that activating ERβ in osteoblasts may promote bone formation while also inhibiting osteoclastogenesis downstream of NF-kB. [3]

The Preclinical Bone Data

Animal models are promising but not directly translatable. A 2014 study in ovariectomized rats found that resveratrol at 20 mg/kg/day significantly increased femoral bone mineral density and trabecular thickness compared with untreated ovariectomized controls. [4] The mechanism involved upregulation of Wnt/β-catenin signaling in osteoblasts alongside reduced RANKL expression, a pathway that partially overlaps with denosumab's target.

Preclinical overlap with RANKL biology does not mean the two agents conflict. It may mean they work on adjacent nodes of the same pathway, which could theoretically be additive or, in edge cases involving supraphysiologic doses, redundant.

Human Clinical Evidence for Resveratrol and Bone

Human data are limited and less conclusive. The REVERSal of Organ Damage in Obesity and Metabolic Syndrome (REMODEL) substudy randomized 74 obese men to resveratrol 1,000 mg/day or placebo for 16 weeks; lumbar spine bone mineral density increased by 2.6% in the resveratrol group versus no change in placebo (P<0.05). [5] This is a small sample and a short duration, and the population (obese men) differs meaningfully from the postmenopausal women who represent most Prolia patients.

The European Menopause and Andropause Society has not yet issued a guideline endorsing resveratrol as an adjunct to anti-resorptive therapy, and no Phase III fracture-endpoint trial of resveratrol exists. [6]

Pharmacokinetic Interaction: Is There a Real CYP3A4 Problem?

The short answer is: not between resveratrol and denosumab directly. Denosumab is entirely CYP-independent. However, if you take other medications alongside both, resveratrol's CYP3A4 activity becomes relevant.

Resveratrol as a CYP3A4 Inhibitor

In vitro data consistently show that resveratrol inhibits CYP3A4. A 2009 pharmacokinetic study in healthy volunteers given resveratrol 1,000 mg as a single oral dose documented a 36% increase in the area under the curve (AUC) of a CYP3A4 probe substrate. [7] At 150 to 500 mg/day, the range most supplement users take, the inhibitory effect is smaller but still detectable in some individuals, particularly those who are CYP3A4 poor metabolizers at baseline.

Drugs commonly co-prescribed with Prolia that are CYP3A4 substrates include corticosteroids (e.g., prednisone), certain calcium-channel blockers, and some bisphosphonates formulated as prodrugs. If you are on any CYP3A4-sensitive drug alongside denosumab, adding resveratrol at doses above 500 mg/day warrants a pharmacist or prescriber review.

Resveratrol and P-glycoprotein

Resveratrol also inhibits P-glycoprotein (P-gp), the efflux transporter encoded by ABCB1. [8] Denosumab is not a P-gp substrate, so this does not create a direct interaction. But co-medications that are P-gp substrates (digoxin, certain immunosuppressants) may have elevated exposure when resveratrol is added.

Bioavailability of Resveratrol Itself

Oral bioavailability of trans-resveratrol is low, typically 1 to 3% due to rapid first-pass glucuronidation and sulfation. This significantly limits systemic exposure and may explain why some predicted pharmacokinetic interactions do not manifest clinically at the lower OTC doses. [9] Higher doses or micronized/liposomal formulations increase bioavailability substantially, which is a reason to flag any "enhanced bioavailability" resveratrol product to your prescriber.

Pharmacodynamic Interaction: Estrogenic Signaling and Bone Remodeling

This is the more nuanced concern for patients combining resveratrol with denosumab.

Resveratrol as a Selective Estrogen Receptor Modulator

Resveratrol binds both ERα and ERβ, with preferential affinity for ERβ. In bone tissue, ERβ activation broadly suppresses osteoclastogenesis. This is the same biological goal that denosumab achieves through a different molecular mechanism. Additive suppression of osteoclast activity sounds appealing, but overcorrection of the bone remodeling cycle carries its own risks.

Severely suppressed bone turnover has been associated with atypical femoral fractures and osteonecrosis of the jaw, risks that the FDA label for Prolia acknowledges. [10] The absolute risk is low, a 2020 systematic review estimated atypical femoral fracture incidence at approximately 3.2 to 50 per 100,000 person-years for anti-resorptive therapy overall, but the concern is not trivial in patients with very low baseline bone turnover. [11]

NF-kB and RANKL Expression: Where the Pathways Converge

Resveratrol reduces RANKL expression in osteoblasts partly through NF-kB inhibition. Denosumab neutralizes RANKL protein in the extracellular space. These are sequential steps in the same signaling cascade. At physiologic resveratrol doses (well below 500 mg/day in most people), the combined reduction in RANKL activity is unlikely to produce clinically meaningful over-suppression. At doses above 1,000 mg/day, especially with high-bioavailability formulations, the theoretical concern rises.

The Estrogen Interaction Question for HRT Users

Some patients on Prolia are also prescribed hormone replacement therapy (HRT). Adding resveratrol as a third agent with estrogenic activity creates a more complex pharmacodynamic picture. No published trial has specifically studied this triple combination. A clinician evaluating bone-turnover markers at 3- to 6-month intervals (specifically, serum C-terminal cross-linking telopeptide of type I collagen, CTX, and procollagen type I N-propeptide, P1NP) would be the practical way to monitor for excessive suppression of bone remodeling in this scenario.

Resveratrol Dose Thresholds: What the Evidence Suggests

Not all resveratrol doses carry the same risk profile. The table below summarizes what the literature suggests at each dose tier.

| Resveratrol Dose | CYP3A4 Inhibition | Estrogenic Activity | Practical Concern with Denosumab | |---|---|---|---| | <150 mg/day (dietary/low-dose) | Minimal | Minimal | Negligible | | 150 to 500 mg/day (standard OTC) | Mild | Low to moderate | Low; discuss with prescriber | | 500 to 1,000 mg/day (high OTC) | Moderate | Moderate | Moderate; monitor bone turnover markers | | >1,000 mg/day (therapeutic/research doses) | Significant | Moderate to high | Higher; advise caution and dose review |

Sources: [7][8][9]

What the Guidelines Say

No major osteoporosis guideline, not the Endocrine Society, the American Association of Clinical Endocrinology (AACE), nor the National Osteoporosis Foundation, has issued a specific recommendation for or against combining resveratrol with denosumab. The absence of a guideline statement reflects the absence of clinical trial data on this combination, not an implicit endorsement.

The AACE/ACE 2020 clinical practice guidelines for postmenopausal osteoporosis state: "Patients should be counseled that dietary supplements, including phytoestrogens, may have biologically active effects on bone metabolism and should be reported to their prescribing clinician." [12]

The Endocrine Society's 2019 pharmacological management guidelines for osteoporosis note that anti-resorptive agents should be managed with awareness of all agents that independently affect bone turnover, including botanical supplements. [13]

The HealthRX Bone Safety Framework for patients combining resveratrol with anti-resorptive therapy assigns a risk tier based on three variables: resveratrol dose, bioavailability formulation (standard vs. Micronized/liposomal), and baseline CTX level at the time of the most recent Prolia injection. Patients with baseline CTX already below 0.1 ng/mL at 3 months post-injection are assigned to the "high monitoring priority" tier regardless of resveratrol dose, because bone turnover is already maximally suppressed by denosumab alone.

Practical Guidance: What to Do If You Are Already Taking Both

Many patients are already combining resveratrol and Prolia before reading this article. Here is a step-by-step approach based on the available evidence.

Step 1: Tell Your Prescriber

Denosumab is a prescription medication with a 6-month dosing schedule. Your prescriber documents your supplement use in the safety monitoring framework established at the start of therapy. A supplement not mentioned during that intake process is a gap in your care record.

Step 2: Get a Baseline CTX Level

Serum CTX (C-terminal telopeptide) drawn in the fasting state is the standard bone resorption marker. The FREEDOM trial used CTX and P1NP as secondary endpoints; both dropped significantly within 1 month of the first Prolia injection. [1] A CTX reading below 0.1 ng/mL at any point during active denosumab therapy suggests maximal anti-resorptive effect. Adding resveratrol on top of maximal suppression is where the theoretical over-suppression concern is strongest.

Step 3: Assess Your Full Medication List for CYP3A4 Substrates

If you take any drug metabolized by CYP3A4, ask your pharmacist for a complete review, then resveratrol doses above 500 mg/day may increase exposure to those drugs. This is independent of the denosumab interaction and is equally important.

Step 4: Choose a Conservative Resveratrol Dose If Continuing

If your clinician agrees resveratrol is appropriate, standard-bioavailability trans-resveratrol at 150 to 500 mg/day represents the dose range with the most favorable benefit-to-risk ratio based on current evidence. Avoid high-bioavailability liposomal or micronized formulations without prescriber guidance.

Step 5: Repeat Bone Turnover Markers at 3 to 6 Months

CTX and P1NP at 3 to 6 months after starting or changing resveratrol dose gives your clinician an objective read on whether osteoclast suppression is within the expected range for denosumab alone.

Special Populations

Postmenopausal Women

Postmenopausal women represent the primary population prescribed Prolia. Estrogen deficiency after menopause increases RANKL expression, which is why osteoclast activity surges and bone loss accelerates. Resveratrol's estrogenic effects via ERβ may provide a small additive anti-resorptive signal, but it is not a substitute for adequate calcium (1,200 mg/day) and vitamin D (800 to 1,000 IU/day) intake, which the NOF guidelines explicitly recommend as co-treatment with any anti-resorptive agent. [14]

Patients on Glucocorticoids

Glucocorticoid-induced osteoporosis (GIOP) is the second most common indication for denosumab. Prednisone and other corticosteroids are CYP3A4 substrates. High-dose resveratrol inhibiting CYP3A4 in a patient on chronic prednisone could increase corticosteroid exposure and glucocorticoid side effects. This is a concrete, clinically meaningful risk in this subgroup. Resveratrol above 500 mg/day is not advisable in patients taking systemic corticosteroids without pharmacist review.

Men with Osteoporosis

Men with osteoporosis, including those on androgen deprivation therapy (ADT) for prostate cancer, may also receive Prolia. Resveratrol's ERβ activity is not relevant only to women; bone tissue in men also expresses estrogen receptors. The REMODEL data cited above were in obese men, suggesting some bone benefit may extend to male patients, but no denosumab-specific male data exist for this combination.

Summary of the Interaction Classification

The resveratrol-denosumab combination does not carry a formal drug-supplement contraindication in any published interaction database, including Natural Medicines (Therapeutic Research Center). The interaction is classified as "minor/theoretical" based on available evidence. [15] The distinction between a theoretical concern and a clinically documented risk is meaningful: it means monitoring is warranted, not avoidance.

"no documented interaction" is not the same as "proven safe at all doses." The clinical evidence base for this specific combination is thin, and resveratrol at doses above 1,000 mg/day in high-bioavailability formulations has not been tested alongside anti-resorptive therapy in a controlled trial.

The most conservative clinical approach is to keep resveratrol at or below 500 mg/day of standard trans-resveratrol, confirm the choice with your Prolia prescriber, and check serum CTX and P1NP 3 to 6 months after starting.